FIELD: organic chemistry, pharmaceutical composition.
SUBSTANCE: compounds satisfying the formula I 
1 are disclosed, wherein each R1 and R2 independently to one another are H, OH, OA or Hal; or R1 and R2 together are -O-CH2-O- or -O-CH2-CH2-O-; R3 and R4 are A-group; X - group monosubstituted with R8, R5 or R7; R5 is linear or branched C1-C10-alkylene, wherein one or two CH2-groups may be substituted with oxygen atom; R7 is phenyl or phenylmethyl; R8 is COOH, COOA, CONH2, CONHA, CON(A)2 or CN; F is C1-C6-alkyl; and Hal is F, Cl, Br, or I, as well as physiologically acceptable salts or solvates thereof. Methods for production of claimed compounds (I) and pharmaceutical composition containing the same also are disclosed. Said compounds and pharmaceutical composition have activity as phosphodiesterase V inhibitors and are useful in treatment of cardiovascular diseases and potency disorders.
EFFECT: pharmaceutically applicable compounds and compositions.
7 cl, 16 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THIENOPYRIMIDINES, METHOD OF THEIR SYNTHESIS (VERSIONS), PHARMACEUTICAL COMPOSITION AND METHOD OF ITS PREPARING | 1997 |
|
RU2199541C2 |
| THIENOPYRIMIDINES WITH INHIBITORY EFFECT WITH RESPECT TO PHOSPHODIESTERASE V (PDE V), METHOD OF THEIR SYNTHESIS AND PHARMACEUTICAL COMPOSITION | 1997 |
|
RU2197492C2 |
| CONDENSED THIENOPYRIMIDINES INHIBITING ACTIVITY OF PHOSPHODIESTERASE V, METHOD FOR THEIR PREPARING AND PHARMACEUTICAL COMPOSITION | 1999 |
|
RU2224760C2 |
| 5-AMINOALKYLPYRAZOLO[4,3-D]PYRIMIDINES | 2001 |
|
RU2271359C2 |
| PHOSPHODIESTERASE TYPE 5 INHIBITOR RELEASING NITROGEN OXIDE | 2019 |
|
RU2785776C2 |
| PYRAZOLOPYRIMIDINES AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS | 1993 |
|
RU2124016C1 |
| NEW COMPOUND FOR IMPOTENCE TREATMENT | 2002 |
|
RU2279433C2 |
| PYRAZOLEPYRIMIDINES | 2005 |
|
RU2412186C2 |
| HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 2017 |
|
RU2742115C2 |
| 4-(IMIDAZO[1,2-A]PYRIDIN-3-YL)-PYRIMIDINE DERIVATIVES | 2020 |
|
RU2822388C2 |
